Future prospects in prostate cancer

Nicholas J. Hegarty, John M. Fitzpatrick, Jerome P. Richie, Peter T. Scardino, Ralph W. DeVere White, Fritz H. Schröder, Donald S. Coffey

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Prostate cancer has displayed an increase in incidence unparalleled by any other tumor in the last two decades, with a steady, more gradual increase in mortality rate. Current curative strategies are focused on the detection and treatment of early-stage (T1-2 N0 M0), clinically significant tumors. METHODS. To this aim, refinement of surgical approaches, with appropriate adjuvant therapies, will ensure more complete cancer control, while minimizing associated morbidity. New delivery systems for radiotherapy, as well as other energy sources, are evolving, while a number of promising pharmacological agents, including angiogenesis inhibitors and drugs which alter signal transduction pathways, are currently under investigation. Early detection is also being facilitated by a more widespread implementation of screening programs. Advances in tumor markers, and imaging and biopsy techniques, will allow more accurate preoperative staging. These, coupled with improvements in prognostic markers, aid the physician and patient alike in deciding on the suitability of treatment options with better estimation of outcome. Perhaps the most exciting developments in prostate cancer will come from knowledge of the molecular mechanisms underlying carcinogenesis. The potential for the development of diagnostic and therapeutic tools is immense. The efficacy of treatment can be studied at a molecular level, and strategies for preventing or slowing the development of malignancy can be formulated. RESULTS AND CONCLUSIONS. Application of this knowledge in the form of gene and cellular therapy and in the development of novel systemic agents is beginning to enter the realm of clinical practice, and it may be in this field that means for cure and prevention of prostate cancer will eventually be found.

Original languageEnglish (US)
Pages (from-to)261-268
Number of pages8
JournalProstate
Volume40
Issue number4
DOIs
StatePublished - 1999

Fingerprint

Prostatic Neoplasms
Neoplasms
Angiogenesis Inhibitors
Therapeutics
Tumor Biomarkers
Genetic Therapy
Signal Transduction
Carcinogenesis
Radiotherapy
Pharmacology
Morbidity
Physicians
Biopsy
Mortality
Incidence
Pharmaceutical Preparations

Keywords

  • Gene therapy
  • Nomograms
  • Prostate cancer
  • Tumor biology

ASJC Scopus subject areas

  • Urology

Cite this

Hegarty, N. J., Fitzpatrick, J. M., Richie, J. P., Scardino, P. T., DeVere White, R. W., Schröder, F. H., & Coffey, D. S. (1999). Future prospects in prostate cancer. Prostate, 40(4), 261-268. https://doi.org/10.1002/(SICI)1097-0045(19990901)40:4<261::AID-PROS8>3.0.CO;2-H

Future prospects in prostate cancer. / Hegarty, Nicholas J.; Fitzpatrick, John M.; Richie, Jerome P.; Scardino, Peter T.; DeVere White, Ralph W.; Schröder, Fritz H.; Coffey, Donald S.

In: Prostate, Vol. 40, No. 4, 1999, p. 261-268.

Research output: Contribution to journalArticle

Hegarty, NJ, Fitzpatrick, JM, Richie, JP, Scardino, PT, DeVere White, RW, Schröder, FH & Coffey, DS 1999, 'Future prospects in prostate cancer', Prostate, vol. 40, no. 4, pp. 261-268. https://doi.org/10.1002/(SICI)1097-0045(19990901)40:4<261::AID-PROS8>3.0.CO;2-H
Hegarty NJ, Fitzpatrick JM, Richie JP, Scardino PT, DeVere White RW, Schröder FH et al. Future prospects in prostate cancer. Prostate. 1999;40(4):261-268. https://doi.org/10.1002/(SICI)1097-0045(19990901)40:4<261::AID-PROS8>3.0.CO;2-H
Hegarty, Nicholas J. ; Fitzpatrick, John M. ; Richie, Jerome P. ; Scardino, Peter T. ; DeVere White, Ralph W. ; Schröder, Fritz H. ; Coffey, Donald S. / Future prospects in prostate cancer. In: Prostate. 1999 ; Vol. 40, No. 4. pp. 261-268.
@article{123c11325311461ca9bc935a1c6db4ae,
title = "Future prospects in prostate cancer",
abstract = "BACKGROUND. Prostate cancer has displayed an increase in incidence unparalleled by any other tumor in the last two decades, with a steady, more gradual increase in mortality rate. Current curative strategies are focused on the detection and treatment of early-stage (T1-2 N0 M0), clinically significant tumors. METHODS. To this aim, refinement of surgical approaches, with appropriate adjuvant therapies, will ensure more complete cancer control, while minimizing associated morbidity. New delivery systems for radiotherapy, as well as other energy sources, are evolving, while a number of promising pharmacological agents, including angiogenesis inhibitors and drugs which alter signal transduction pathways, are currently under investigation. Early detection is also being facilitated by a more widespread implementation of screening programs. Advances in tumor markers, and imaging and biopsy techniques, will allow more accurate preoperative staging. These, coupled with improvements in prognostic markers, aid the physician and patient alike in deciding on the suitability of treatment options with better estimation of outcome. Perhaps the most exciting developments in prostate cancer will come from knowledge of the molecular mechanisms underlying carcinogenesis. The potential for the development of diagnostic and therapeutic tools is immense. The efficacy of treatment can be studied at a molecular level, and strategies for preventing or slowing the development of malignancy can be formulated. RESULTS AND CONCLUSIONS. Application of this knowledge in the form of gene and cellular therapy and in the development of novel systemic agents is beginning to enter the realm of clinical practice, and it may be in this field that means for cure and prevention of prostate cancer will eventually be found.",
keywords = "Gene therapy, Nomograms, Prostate cancer, Tumor biology",
author = "Hegarty, {Nicholas J.} and Fitzpatrick, {John M.} and Richie, {Jerome P.} and Scardino, {Peter T.} and {DeVere White}, {Ralph W.} and Schr{\"o}der, {Fritz H.} and Coffey, {Donald S.}",
year = "1999",
doi = "10.1002/(SICI)1097-0045(19990901)40:4<261::AID-PROS8>3.0.CO;2-H",
language = "English (US)",
volume = "40",
pages = "261--268",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Future prospects in prostate cancer

AU - Hegarty, Nicholas J.

AU - Fitzpatrick, John M.

AU - Richie, Jerome P.

AU - Scardino, Peter T.

AU - DeVere White, Ralph W.

AU - Schröder, Fritz H.

AU - Coffey, Donald S.

PY - 1999

Y1 - 1999

N2 - BACKGROUND. Prostate cancer has displayed an increase in incidence unparalleled by any other tumor in the last two decades, with a steady, more gradual increase in mortality rate. Current curative strategies are focused on the detection and treatment of early-stage (T1-2 N0 M0), clinically significant tumors. METHODS. To this aim, refinement of surgical approaches, with appropriate adjuvant therapies, will ensure more complete cancer control, while minimizing associated morbidity. New delivery systems for radiotherapy, as well as other energy sources, are evolving, while a number of promising pharmacological agents, including angiogenesis inhibitors and drugs which alter signal transduction pathways, are currently under investigation. Early detection is also being facilitated by a more widespread implementation of screening programs. Advances in tumor markers, and imaging and biopsy techniques, will allow more accurate preoperative staging. These, coupled with improvements in prognostic markers, aid the physician and patient alike in deciding on the suitability of treatment options with better estimation of outcome. Perhaps the most exciting developments in prostate cancer will come from knowledge of the molecular mechanisms underlying carcinogenesis. The potential for the development of diagnostic and therapeutic tools is immense. The efficacy of treatment can be studied at a molecular level, and strategies for preventing or slowing the development of malignancy can be formulated. RESULTS AND CONCLUSIONS. Application of this knowledge in the form of gene and cellular therapy and in the development of novel systemic agents is beginning to enter the realm of clinical practice, and it may be in this field that means for cure and prevention of prostate cancer will eventually be found.

AB - BACKGROUND. Prostate cancer has displayed an increase in incidence unparalleled by any other tumor in the last two decades, with a steady, more gradual increase in mortality rate. Current curative strategies are focused on the detection and treatment of early-stage (T1-2 N0 M0), clinically significant tumors. METHODS. To this aim, refinement of surgical approaches, with appropriate adjuvant therapies, will ensure more complete cancer control, while minimizing associated morbidity. New delivery systems for radiotherapy, as well as other energy sources, are evolving, while a number of promising pharmacological agents, including angiogenesis inhibitors and drugs which alter signal transduction pathways, are currently under investigation. Early detection is also being facilitated by a more widespread implementation of screening programs. Advances in tumor markers, and imaging and biopsy techniques, will allow more accurate preoperative staging. These, coupled with improvements in prognostic markers, aid the physician and patient alike in deciding on the suitability of treatment options with better estimation of outcome. Perhaps the most exciting developments in prostate cancer will come from knowledge of the molecular mechanisms underlying carcinogenesis. The potential for the development of diagnostic and therapeutic tools is immense. The efficacy of treatment can be studied at a molecular level, and strategies for preventing or slowing the development of malignancy can be formulated. RESULTS AND CONCLUSIONS. Application of this knowledge in the form of gene and cellular therapy and in the development of novel systemic agents is beginning to enter the realm of clinical practice, and it may be in this field that means for cure and prevention of prostate cancer will eventually be found.

KW - Gene therapy

KW - Nomograms

KW - Prostate cancer

KW - Tumor biology

UR - http://www.scopus.com/inward/record.url?scp=0032791832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032791832&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0045(19990901)40:4<261::AID-PROS8>3.0.CO;2-H

DO - 10.1002/(SICI)1097-0045(19990901)40:4<261::AID-PROS8>3.0.CO;2-H

M3 - Article

C2 - 10420155

AN - SCOPUS:0032791832

VL - 40

SP - 261

EP - 268

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 4

ER -